Lv5
1570 积分 2020-08-30 加入
Mid-Treatment Positron Emission Tomography–Adaptive Radiotherapy in Stage III Non–Small Cell Lung Cancer: Another Attempt Toward Personalized Care
5个月前
已完结
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
5个月前
已完结
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial
6个月前
已完结
Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis
6个月前
已完结
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
6个月前
已完结
Fully Automated Online Adaptive Radiotherapy Decision Making for Cervical Cancer Using Artificial Intelligence
7个月前
已完结
Nanoparticles-Mediated Intratumoral Gene Editing Targeting PD-L1 and Galectin-9 for Improved Cancer Immunotherapy
9个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
9个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
9个月前
已完结
皖公网安备34019202002308
